Table of Contents Author Guidelines Submit a Manuscript
Biochemistry Research International
Volume 2016 (2016), Article ID 3204818, 7 pages
http://dx.doi.org/10.1155/2016/3204818
Research Article

Changes in Lipid Profiles of HIV+ Adults over Nine Months at a Harare HIV Clinic: A Longitudinal Study

1Institute of Clinical Medicine, University in Oslo, Oslo University Hospital, P.O. Box 1171, Blindern, 0318 Oslo, Norway
2Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, P.O. Box AV 178, Avondale, Harare, Zimbabwe
3Division of Community Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg, Cape Town 7505, South Africa
4Department of Infectious Diseases, Oslo University Hospital, P.O. Box 4950, Nydalen, 0424 Oslo, Norway
5Department of Chemical Pathology, College of Health Sciences, University of Zimbabwe, P.O. Box AV 178, Avondale, Harare, Zimbabwe
6Centre for Evidence-Based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg, Cape Town 7505, South Africa

Received 30 September 2015; Revised 12 January 2016; Accepted 8 February 2016

Academic Editor: John Voss

Copyright © 2016 Danai Tavonga Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “National AIDS Council Preliminary Report,” December 2015, http://www.nac.org.zw/category/tags/hiv-and-aids-zimbabwe.
  2. Zimbabwe UNAIDS Report, http://www.unaids.org/en/regionscountries/countries/zimbabwe.
  3. S. G. Deeks, S. R. Lewin, and D. V. Havlir, “The end of AIDS: HIV infection as a chronic disease,” The Lancet, vol. 382, no. 9903, pp. 1525–1533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe, National Medicine and Therapeutics Policy Advisory Committee (NMTPAC), The AIDS and TB Directorate, Ministry of Health and Child Care, Harare, Zimbabwe, 2013.
  5. C. F. Gilks, S. Crowley, R. Ekpini et al., “The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings,” The Lancet, vol. 368, no. 9534, pp. 505–510, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. WHO, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach, WHO, 2013.
  7. A. G. Cotter, C. S. Satchell, J. A. O'Halloran, E. R. Feeney, C. A. Sabin, and P. W. G. Mallon, “High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients,” AIDS, vol. 25, no. 6, pp. 867–869, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. R. H. Haubrich, S. A. Riddler, A. G. DiRienzo et al., “Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment,” AIDS, vol. 23, no. 9, pp. 1109–1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Galli, A. L. Ridolfo, F. Adorni et al., “Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors,” Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 1, pp. 21–31, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. E. R. Feeney and P. W. G. Mallon, “HIV and HAART-associated dyslipidemia,” The Open Cardiovascular Medicine Journal, vol. 5, pp. 49–63, 2011. View at Publisher · View at Google Scholar
  11. E. Bernal, M. Masiá, S. Padilla, and F. Gutiérrez, “High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition,” AIDS Patient Care and STDs, vol. 22, no. 7, pp. 569–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Estrada and J. Portilla, “Dyslipidemia related to antiretroviral therapy,” AIDS Reviews, vol. 13, no. 1, pp. 49–56, 2011. View at Google Scholar · View at Scopus
  13. E. W. P. Yone, A. P. Kengne, G. Ashuntantang, A. F. Betyoumin, and J. Ngogang, “Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study,” BMJ Open, vol. 2, no. 4, Article ID e001317, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Van Der Valk, J. J. P. Kastelein, R. L. Murphy et al., “Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile,” AIDS, vol. 15, no. 18, pp. 2407–2414, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Fontas, F. Van Leth, C. A. Sabin et al., “Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?” The Journal of Infectious Diseases, vol. 189, no. 6, pp. 1056–1074, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Weidle, N. Wamai, P. Solberg et al., “Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda,” The Lancet, vol. 368, no. 9547, pp. 1587–1594, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Padmapriyadarsini, S. R. Kumar, N. Terrin et al., “Dyslipidemia among HIV-infected patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India,” Clinical Infectious Diseases, vol. 52, no. 4, pp. 540–546, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. L. Montes, F. Pulido, C. Barros et al., “Lipid disorders in antiretroviral-naïve patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 5, pp. 800–804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Zhou, V. Kodogo, K. Chokuona, O. Oktedalen, B. Stray-Pedersen, and E. Gomo, “Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe,” HIV/AIDS—Research and Palliative Care, vol. 2015, no. 7, pp. 145–155, 2015. View at Publisher · View at Google Scholar
  20. “NECP Expert Panel on detection and early treatment of high blood cholesterol in adults: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) Final report,” Circulation, vol. 106, article 3143, 2002.
  21. E. Eren, N. Yilmaz, and O. Aydin, “High density lipoprotein and it's dysfunction,” Open Biochemistry Journal, vol. 6, pp. 78–93, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. A. Riddler, X. Li, H. Chu et al., “Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy,” HIV Medicine, vol. 8, no. 5, pp. 280–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Buchacz, P. J. Weidle, D. Moore et al., “Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda,” Journal of Acquired Immune Deficiency Syndromes, vol. 47, no. 3, pp. 304–311, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. C. Achhra, J. Amin, J. Hoy et al., “Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and Australia,” AIDS Research and Treatment, vol. 2012, Article ID 246280, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Cerrato, A. Calcagno, F. D'Ascenzo et al., “Cardiovascular disease in HIV patients: from bench to bedside and backwards,” Open Heart, vol. 2, no. 1, Article ID e000174, 2015. View at Publisher · View at Google Scholar
  26. Z. A. R. Gomo, J. G. Hakim, S. A. Walker et al., “Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study,” AIDS Research and Therapy, vol. 11, article 32, 2014. View at Publisher · View at Google Scholar
  27. J. A. George, W. D. F. Venter, H. E. Van Deventer, and N. J. Crowther, “A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine,” AIDS Research and Human Retroviruses, vol. 25, no. 8, pp. 771–781, 2009. View at Publisher · View at Google Scholar · View at Scopus